{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:11:22Z","timestamp":1776316282944,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41433-023-02800-9","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T18:04:58Z","timestamp":1698343498000},"page":"893-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-7739","authenticated-orcid":false,"given":"Furkan","family":"\u00c7am","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hande","family":"Celiker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"2800_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/jir.2011.0065","volume":"31","author":"KD Moudgil","year":"2011","unstructured":"Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res. 2011;31:695\u2013703. https:\/\/doi.org\/10.1089\/jir.2011.0065.","journal-title":"J Interferon Cytokine Res"},{"key":"2800_CR2","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, Nguyen QD, Thorne JE, Kestelyn P. et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016;375:932\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1509852.","journal-title":"N Engl J Med"},{"key":"2800_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000055677","volume":"33","author":"M Santos Lacomba","year":"2001","unstructured":"Santos Lacomba M, Marcos Mart\u00edn C, Gallardo Galera JM, G\u00f3mez Vidal MA, Collantes Est\u00e9vez E, Ram\u00edrez Chamond R. et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251\u20135. https:\/\/doi.org\/10.1159\/000055677.","journal-title":"Ophthalmic Res"},{"key":"2800_CR4","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1136\/bjophthalmol-2018-312767","volume":"105","author":"SM Sharma","year":"2021","unstructured":"Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R. et al. Long-term efficacy and tolerability of TNF\u03b1 inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study. Br J Ophthalmol. 2021;105:1256\u201362. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312767.","journal-title":"Br J Ophthalmol"},{"key":"2800_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/09273948.2015.1134581","volume":"25","author":"K Durrani","year":"2017","unstructured":"Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JT. et al. Adalimumab for Ocular Inflammation. Ocul Immunol Inflamm. 2017;25:405\u201312. https:\/\/doi.org\/10.3109\/09273948.2015.1134581.","journal-title":"Ocul Immunol Inflamm"},{"key":"2800_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","volume":"97","author":"EB Suhler","year":"2013","unstructured":"Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA. et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97:481\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302292.","journal-title":"Br J Ophthalmol"},{"key":"2800_CR7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(16)31339-3.","journal-title":"Lancet."},{"key":"2800_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785\u201396.e3. https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.048.","journal-title":"Ophthalmology."},{"key":"2800_CR9","doi-asserted-by":"publisher","first-page":"862969.","DOI":"10.1155\/2014\/862969","volume":"2014","author":"M Fabbroni","year":"2014","unstructured":"Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B. et al. Drug retention rates and treatment discontinuation among anti-TNF-\u03b1 agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm. 2014;2014:862969. https:\/\/doi.org\/10.1155\/2014\/862969.","journal-title":"Mediators Inflamm"},{"key":"2800_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/rheumatology\/kev374","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, G\u00f3mez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology. 2016;55:523\u201334. https:\/\/doi.org\/10.1093\/rheumatology\/kev374.","journal-title":"Rheumatology"},{"key":"2800_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.ophtha.2019.11.024","volume":"127","author":"V Lloren\u00e7","year":"2020","unstructured":"Lloren\u00e7 V, Cordero-Coma M, Blanco-Esteban A, Heras-Mulero H, Losada-Castillo MJ, Jovani-Casano V. et al. Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (Bio\u00davea) Study Group. Ophthalmology. 2020;127:814\u201325. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.024.","journal-title":"Ophthalmology"},{"key":"2800_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/bjophthalmol-2017-310733","volume":"102","author":"C Fabiani","year":"2018","unstructured":"Fabiani C, Sota J, Vitale A, Rigante D, Emmi G, Vannozzi L, et al. Cumulative retention rate of adalimumab in patients with Beh\u00e7et\u2019s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2018;102:637\u201341. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310733.","journal-title":"Br J Ophthalmol"},{"key":"2800_CR13","doi-asserted-by":"publisher","first-page":"1623847","DOI":"10.1155\/2019\/1623847","volume":"2019","author":"A Bitossi","year":"2019","unstructured":"Bitossi A, Bettiol A, Silvestri E, Di Scala G, Bacherini D, Lopalco G, et al. Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. Mediators Inflamm. 2019;2019:1623847. https:\/\/doi.org\/10.1155\/2019\/1623847.","journal-title":"Mediators Inflamm"},{"key":"2800_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10067-018-4069-3","volume":"38","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Vitale A, Emmi G, Bitossi A, Lopalco G, Sota J. et al. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clin Rheumatol. 2019;38:63\u201370. https:\/\/doi.org\/10.1007\/s10067-018-4069-3.","journal-title":"Clin Rheumatol"},{"key":"2800_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT.Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509\u201316. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057.","journal-title":"Am J Ophthalmol"},{"key":"2800_CR16","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","volume":"125","author":"EB Suhler","year":"2018","unstructured":"Suhler EB, Ad\u00e1n A, Br\u00e9zin AP, Fortin E, Goto H, Jaffe GJ. et al. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology. 2018;125:1075\u201387. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.039.","journal-title":"Ophthalmology"},{"key":"2800_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajo.2022.03.017","volume":"240","author":"LEM Eurelings","year":"2022","unstructured":"Eurelings LEM, Missotten TOAR, van Velthoven MEJ, van Daele PLA, van Laar JAM, van Hagen PM. et al. Long-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy. Am J Ophthalmol. 2022;240:194\u2013204. https:\/\/doi.org\/10.1016\/j.ajo.2022.03.017.","journal-title":"Am J Ophthalmol"},{"key":"2800_CR18","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1080\/09273948.2020.1749857","volume":"29","author":"P Liberman","year":"2021","unstructured":"Liberman P, Berkenstock MK, Burkholder BM, Chaon BC, Thorne JE. Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation. Ocul Immunol Inflamm. 2021;29:1564\u20138. https:\/\/doi.org\/10.1080\/09273948.2020.1749857.","journal-title":"Ocul Immunol Inflamm"},{"key":"2800_CR19","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.ophtha.2020.04.009","volume":"127","author":"J Lee","year":"2020","unstructured":"Lee J, Koreishi AF, Zumpf KB, Minkus CL, Goldstein DA. Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease. Ophthalmology. 2020;127:1431\u20133. https:\/\/doi.org\/10.1016\/j.ophtha.2020.04.009.","journal-title":"Ophthalmology"},{"key":"2800_CR20","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","volume":"125","author":"JL Mart\u00edn-Varillas","year":"2018","unstructured":"Mart\u00edn-Varillas JL, Calvo-R\u00edo V, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Mesquida M, Ad\u00e1n A. et al. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Beh\u00e7et\u2019s Disease. Ophthalmology. 2018;125:1444\u201351. https:\/\/doi.org\/10.1016\/j.ophtha.2018.02.020.","journal-title":"Ophthalmology"},{"key":"2800_CR21","doi-asserted-by":"publisher","first-page":"e0175207.","DOI":"10.1371\/journal.pone.0175207","volume":"12","author":"RJ Moots","year":"2017","unstructured":"Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH. et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12:e0175207. https:\/\/doi.org\/10.1371\/journal.pone.0175207.","journal-title":"PLoS One"},{"key":"2800_CR22","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1016\/j.ophtha.2016.08.025","volume":"123","author":"M Cordero-Coma","year":"2016","unstructured":"Cordero-Coma M, Calleja-Antol\u00edn S, Garzo-Garc\u00eda I, Nu\u00f1ez-Garn\u00e9s AM, \u00c1lvarez-Castro C, Franco-Benito M. et al. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies. Ophthalmology.2016;123:2618\u201325. https:\/\/doi.org\/10.1016\/j.ophtha.2016.08.025.","journal-title":"Ophthalmology."},{"key":"2800_CR23","doi-asserted-by":"publisher","first-page":"e001047.","DOI":"10.1136\/rmdopen-2019-001047","volume":"6","author":"E Ducourau","year":"2020","unstructured":"Ducourau E, Rispens T, Samain M, Dernis E, Le Guilchard F, Andras L. et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open. 2020;6:e001047. https:\/\/doi.org\/10.1136\/rmdopen-2019-001047.","journal-title":"RMD Open"},{"key":"2800_CR24","first-page":"1043","volume":"35","author":"ST Leinonen","year":"2017","unstructured":"Leinonen ST, Aalto K, Kotaniemi KM, Kivel\u00e4 TT. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol. 2017;35:1043\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"2800_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S. et al. Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36:183\u20139. https:\/\/doi.org\/10.1007\/s10067-016-3480-x.","journal-title":"Clin Rheumatol"},{"key":"2800_CR26","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.2147\/DDDT.S160431","volume":"12","author":"S Ming","year":"2018","unstructured":"Ming S, Xie K, He H, Li Y, Lei B. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther. 2018;12:2005\u201316. https:\/\/doi.org\/10.2147\/DDDT.S160431.","journal-title":"Drug Des Devel Ther"},{"key":"2800_CR27","doi-asserted-by":"publisher","first-page":"673984","DOI":"10.3389\/fphar.2021.673984","volume":"12","author":"B Li","year":"2021","unstructured":"Li B, Li H, Zhang L, Zheng Y. Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2021;12:673984. https:\/\/doi.org\/10.3389\/fphar.2021.673984.","journal-title":"Front Pharmacol"},{"key":"2800_CR28","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","volume":"119","author":"M D\u00edaz-Llopis","year":"2012","unstructured":"D\u00edaz-Llopis M, Salom D, Garcia-de-Vicu\u00f1a C, Cordero-Coma M, Ortega G, Ortego N. et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575\u201381. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.018.","journal-title":"Ophthalmology"},{"key":"2800_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/bjophthalmol-2011-301401","volume":"97","author":"BC Dobner","year":"2013","unstructured":"Dobner BC, Max R, Becker MD, Heinz C, Veltrup I, Heiligenhaus A. et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301401.","journal-title":"Br J Ophthalmol"},{"key":"2800_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3349\/ymj.2021.62.2.177","volume":"62","author":"SE Park","year":"2021","unstructured":"Park SE, Jun JW, Lee DH, Lee SC, Kim M. The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis. Yonsei Med J. 2021;62:177\u201381. https:\/\/doi.org\/10.3349\/ymj.2021.62.2.177.","journal-title":"Yonsei Med J"},{"key":"2800_CR31","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/09273948.2018.1498110","volume":"26","author":"R Lejoyeux","year":"2018","unstructured":"Lejoyeux R, Diwo E, Vallet H, Saadoun D, Tezenas du Montcel S, Bodaghi B. et al. INFLIXIMAB and ADALIMUMAB in Uveitic Macular Edema. Ocul Immunol Inflamm. 2018;26:991\u20136. https:\/\/doi.org\/10.1080\/09273948.2018.1498110.","journal-title":"Ocul Immunol Inflamm"},{"key":"2800_CR32","doi-asserted-by":"publisher","first-page":"e000819","DOI":"10.1136\/bmjophth-2021-000819","volume":"6","author":"TL Tang Lee Say","year":"2021","unstructured":"Tang Lee Say TL, Yang V, Fingret JM, Zagora S, Symes R, Younan C. et al. Adalimumab in patients with vision-threatening uveitis: real-world clinical experience. BMJ Open Ophthalmol. 2021;6:e000819. https:\/\/doi.org\/10.1136\/bmjophth-2021-000819.","journal-title":"BMJ Open Ophthalmol"},{"key":"2800_CR33","first-page":"241","volume":"28","author":"C \u00c7eki\u00e7","year":"2015","unstructured":"\u00c7eki\u00e7 C, Aslan F, Vatansever S, Topal F, Y\u00fcksel ES, Alper E, et al. Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy. Ann Gastroenterol. 2015;28:241\u20136.","journal-title":"Ann Gastroenterol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02800-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02800-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02800-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T12:04:21Z","timestamp":1711454661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02800-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2800"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02800-9","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Institutional Review Board of Marmara University School of Medicine Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was performed following the Declaration of Helsinki principles, and all patients provided written informed consent about having their medical information used in the study analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}